Balyasny Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Balyasny Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.27M	Buy	+31,023	New	+$7.25M	0.01%	1131
2026 Q1	–	Sell	-24,079	Closed	-$5.13M	–	2874
2025 Q4	$5.13M	Buy	+24,079	New	+$4.97M	0.01%	1379
2025 Q1	–	Sell	-15,419	Closed	-$2.12M	–	2776
2024 Q4	$2.12M	Buy	+15,419	New	+$2.03M	﹤0.01%	1652
2024 Q3	–	Sell	-4,221	Closed	-$576K	–	2727
2024 Q2	$576K	Buy	+4,221	New	+$574K	﹤0.01%	2005
2023 Q4	–	Sell	-94,868	Closed	-$8.88M	–	2482
2023 Q3	$8.88M	Buy	+94,868	New	+$8.88M	0.02%	892
2023 Q2	–	Sell	-13,394	Closed	-$1.44M	–	2258
2023 Q1	$1.44M	Sell	13,394 -40,103	-75%	-$4.59M	﹤0.01%	1599
2022 Q4	$6.53M	Buy	+53,497	New	+$6.21M	0.02%	916

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Balyasny Asset Management's ASND Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 31,023 shares worth $8.27M. The stake represents 0.01% of the portfolio and ranks #1131 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ASND as recently as Q4 2025.

Balyasny Asset Management first reported a position in ASND in Q4 2022 and has held it in 7 quarters since. The position peaked at $8.88M in Q3 2023. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Balyasny Asset Management held 31,023 shares of Ascendis Pharma A/S worth $8.27M as of Q2 2026.
Ascendis Pharma A/S was a new Balyasny Asset Management position in Q2 2026.
Ascendis Pharma A/S made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1131 holding.
Balyasny Asset Management first reported a position in Ascendis Pharma A/S in Q4 2022 and has held it in 7 quarters since.
Balyasny Asset Management's Ascendis Pharma A/S position peaked at $8.88M in Q3 2023.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.